Metabolic Syndrome and NASH

Clinics in Liver Disease

Volumn 11, Issue 1, 2007, Pages 105-117

  Marchesini, Giulio ^a   Marzocchi, Rebecca ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INSULIN SENSITIZING AGENT; METFORMIN; PIOGLITAZONE;

AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; FATTY LIVER; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOBETALIPOPROTEINEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER FUNCTION TEST; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUTRITIONAL ASSESSMENT; OBESITY; REVIEW; RISK FACTOR; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

FATTY LIVER; HEPATITIS; HUMANS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 34249711303     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.02.013     Document Type: Review

References (70)

1. Ludwig J., Viggiano T.R., McGill D.B., et al. Nonalcoholic steatohepatitis: Mayo Clinic experience with an hitherto unnamed disease. Mayo Clin Proc 55 7 (1980) 434-438
2. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human diabetes. Diabetes 37 12 (1988) 1595-1607
3. Marchesini G., Brizi M., Morselli-Labate A.M., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107 5 (1999) 450-455
4. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 8 (2001) 1844-1850
5. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 15 7 (1998) 539-553
6. Balkau B., Charles M.A., and for the European Group for the Study of Insulin Resistance (EGIR). Comment on the provisional report from the WHO consultation. Diabet Med 16 5 (1999) 442-443
7. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 19 (2001) 2486-2497
8. Einhorn D., Reaven G.M., Cobin R.H., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9 3 (2003) 237-252
9. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366 9491 (2005) 1059-1062
10. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia 28 7 (1985) 412-419
11. McLaughlin T., Abbasi F., Cheal K., et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139 10 (2003) 802-809
12. Liao Y., Kwon S., Shaughnessy S., et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 27 4 (2004) 978-983
13. Shen B.J., Todaro J.F., Niaura R., et al. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 157 8 (2003) 701-711
14. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 21 (2002) 2709-2716
15. Meigs J.B., Wilson P.W., Nathan D.M., et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 52 8 (2003) 2160-2167
16. Ford E.S. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173 2 (2004) 309-314
17. McNeill A.M., Rosamond W.D., Girman C.J., et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 28 2 (2005) 385-390
18. Girman C.J., Rhodes T., Mercuri M., et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93 2 (2004) 136-141
19. Klein B.E., Klein R., and Lee K.E. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 25 10 (2002) 1790-1794
20. Reaven G.M. The metabolic syndrome: requiescat in pace. Clin Chem 51 6 (2005) 931-938
21. Kahn R., Buse J., Ferrannini E., et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 9 (2005) 2289-2304
22. Hu F.B., van Dam R.M., and Liu S. Diet and risk of Type II diabetes: the role of types of fat and carbohydrate. Diabetologia 44 7 (2001) 805-817
23. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 5 (2001) 1183-1192
24. Seppala-Lindroos A., Vehkavaara S., Hakkinen A.M., et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87 7 (2002) 3023-3028
25. Bugianesi E., Gastaldelli A., Vanni E., et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48 4 (2005) 634-642
26. Shen Y.H., Yang W.S., Lee T.H., et al. Bright liver and alanine aminotransferase are associated with metabolic syndrome in adults. Obes Res 13 7 (2005) 1238-1245
27. Bedogni G., Miglioli L., Masutti F., et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42 1 (2005) 44-52
28. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 4 (2003) 917-923
29. Haukeland J.W., Konopski Z., Linnestad P., et al. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 40 12 (2005) 1469-1477
30. Pagano G., Pacini G., Musso G., et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35 2 (2002) 367-372
31. Balkau B. New diagnostic criteria for diabetes and mortality in older adults. DECODE Study Group. European Diabetes Epidemiology Group. Lancet 353 9146 (1999) 68-69
32. Marchesini G., Bugianesi E., Forlani G., et al. Non-alcoholic steatohepatitis in patients cared in metabolic units. Diabetes Res Clin Pract 63 2 (2004) 143-151
33. Villanova N., Moscatiello S., Ramilli S., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42 2 (2005) 473-480
34. Brea A., Mosquera D., Martin E., et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis. A case-control study. Arterioscler Thromb Vasc Biol 25 May (2005) 1045-1050
35. Volzke H., Robinson D.M., Kleine V., et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 11 12 (2005) 1848-1853
36. Targher G., Bertolini L., Padovani R., et al. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 27 10 (2004) 2498-2500
37. Targher G., Bertolini L., Poli F., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54 12 (2005) 3541-3546
38. Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132 2 (2000) 112-117
39. Clark J.M., Brancati F.L., and Diehl A.M. Nonalcoholic fatty liver disease. Gastroenterology 122 6 (2002) 1649-1657
40. Sabir N., Sermez Y., Kazil S., et al. Correlation of abdominal fat accumulation and liver steatosis: importance of ultrasonographic and anthropometric measurements. Eur J Ultrasound 14 2-3 (2001) 121-128
41. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363 9403 (2004) 157-163
42. Carr D.B., Utzschneider K.M., Hull R.L., et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53 8 (2004) 2087-2094
43. Yusuf S., Hawken S., Ounpuu S., et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366 9497 (2005) 1640-1649
44. Marchesini G., Avagnina S., Barantani E.G., et al. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest 28 4 (2005) 333-339
45. Marceau P., Biron S., Hould F.S., et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 84 5 (1999) 1513-1517
46. Ioannou G.N., Weiss N.S., Kowdley K.V., et al. Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology 125 4 (2003) 1053-1059
47. Marchesini G., Forlani G., and Bugianesi E. Is liver disease a threat to patients with metabolic disorders?. Ann Med 37 5 (2005) 333-346
48. Nair S., Mason A., Eason J., et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology 36 1 (2002) 150-155
49. Jimba S., Nakagami T., Takahashi M., et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 22 9 (2005) 1141-1145
50. Vozarova B., Stefan N., Lindsay R.S., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 51 6 (2002) 1889-1895
51. Angulo P., Keach J.C., Batts K.P., et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30 6 (1999) 1356-1362
52. Adams L.A., Sanderson S., Lindor K.D., et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42 1 (2005) 132-138
53. Caldwell S.H., Crespo D.M., Kang H.S., et al. Obesity and hepatocellular carcinoma. Gastroenterology 127 5 Suppl 1 (2004) S97-S103
54. de Marco R., Locatelli F., Zoppini G., et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 22 5 (1999) 756-761
55. Verlato G., Zoppini G., Bonora E., et al. Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 26 4 (2003) 1047-1051
56. Davila J.A., Morgan R.O., Shaib Y., et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54 4 (2005) 533-539
57. Ikai E., Ishizaki M., Suzuki Y., et al. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 9 2 (1995) 101-105
58. Akahoshi M., Amasaki Y., Soda M., et al. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens Res 24 4 (2001) 337-343
59. Donati G., Stagni B., Piscaglia F., et al. Increased prevalence of fatty liver in arterial hypertensive patients. Role of insulin resistance. Gut 53 7 (2004) 1020-1023
60. Assy N., Kaita K., Mymin D., et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 45 10 (2000) 1929-1934
61. Lonardo A., Lombardini S., Scaglioni F., et al. Hepatic steatosis and insulin resistance: does etiology make a difference?. J Hepatol 44 1 (2006) 190-196
62. Tanoli T., Yue P., Yablonskiy D., et al. Fatty liver in familial hypobetalipoproteinemia: roles of the ApoB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res 45 5 (2004) 941-947
63. Tilg H., and Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2 3 (2005) 148-155
64. Saris W.H., Blair S.N., van Baak M.A., et al. How much physical activity is enough to prevent unhealthy weight gain? Outcome of the IASO 1st Stock Conference and consensus statement. Obes Rev 4 2 (2003) 101-114
65. Huang M.A., Greenson J.K., Chao C., et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 100 5 (2005) 1072-1081
66. Suzuki A., Lindor K., St Sauver J., et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 43 6 (2005) 1060-1066
67. Bugianesi E., Gentilcore E., Manini R., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100 5 (2005) 1082-1090
68. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 9493 (2005) 1279-1289
69. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 2 Suppl 1 (2006) S99-S112
70. Marchesini G., Ronchi M., Forlani G., et al. Cardiovascular disease in cirrhosis-a point-prevalence study in relation to glucose tolerance. Am J Gastroenterol 94 3 (1999) 655-662